Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents

S. Zenvirt, N. Kravchenko-Balasha, A. Levitzki*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

46 Scopus citations

Abstract

DNA damage checkpoints cause cell cycle arrest, allowing DNA repair before resumption of the cell cycle. These checkpoints can be activated through several signaling pathways. Checkpoint activators include p53, checkpoint kinase 1 (CHK1), checkpoint kinase 2 and/or MAPKAP kinase 2 (MK2). Many cancer cells lack p53 activity and, therefore, depend on alternative checkpoint activators to arrest the cell cycle following DNA damage. Inhibition of these pathways is expected to specifically sensitize these p53-deficient cells to DNA damage caused by chemotherapy. Using isogenic p53-proficient and p53-deficient cancer cell lines, we show that inactivation of CHK1, but not MK2, abrogates cell cycle arrest following chemotherapy, specifically in p53-deficient cells. However, we show that CHK1 is required to maintain genome integrity and cell viability, and that p53-proficient cells are no less sensitive than p53-deficient cells to CHK1 inhibition in the presence of DNA damage. Thus, combining CHK1 inhibition with DNA damage does not lead to preferential killing of p53-deficient over p53-proficient cells, and inhibiting CHK1 does not appear to be a promising approach for potentiation of cancer chemotherapy.

Original languageAmerican English
Pages (from-to)6149-6159
Number of pages11
JournalOncogene
Volume29
Issue number46
DOIs
StatePublished - 18 Nov 2010

Bibliographical note

Funding Information:
We would like to thank Dr Shoshana Klein for discussions and editing. This work was partially supported by the Lady Davis Fellowship Trust and by Algen Biopharmaceuticals, Ltd.

Keywords

  • CHK1
  • cancer
  • checkpoint
  • p53

Fingerprint

Dive into the research topics of 'Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents'. Together they form a unique fingerprint.

Cite this